Journal
ONCOIMMUNOLOGY
Volume 1, Issue 2, Pages 179-188Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.1.2.19026
Keywords
autophagy; ATP; calreticulin; HMGB1; HSP70; interferon gamma
Categories
Funding
- Ligue contre le Cancer (equipes labelisees)
- AXA Chair for Longevity Research
- Canceropole Ile-de-France
- Institut National du Cancer (INCa)
- Fondation Bettencourt-Schueller
- Fondation de France
- Fondation pour la Recherche Medicale
- Agence National de la Recherche
- European Commission (Apo-Sys, ArtForce, ChemoRes. Death-Train)
- LabEx Immuno-Oncology
Ask authors/readers for more resources
The long-established notion that apoptosis would be immunologically silent, and hence it would go unnoticed by the immune system, if not tolerogenic, and hence it would actively suppress immune responses, has recently been revisited. In some instances, indeed, cancer cells undergo apoptosis while emitting a spatiotemporally-defined combination of signals that renders them capable of eliciting a long-term protective antitumor immune response. Importantly, only a few anticancer agents can stimulate such an immunogenic cell death. These include cyclophosphamide, doxorubicin and oxaliplatin, which are currently approved by FDA for the treatment of multiple hematologic and solid malignancies, as well as mitoxantrone, which is being used in cancer therapy and against multiple sclerosis. In this Trial Watch, we will review and discuss the progress of recent (initiated after January 2008) clinical trials evaluating the off-label use of cyclophosphamide, doxorubicin, oxaliplatin and mitoxantrone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available